article thumbnail

Eisai wins over European regulators on Alzheimer’s drug Leqembi

Bio Pharma Dive

But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market. A key regulatory committee sided against the drug this summer.

article thumbnail

Leqembi voted down by European regulators

Bio Pharma Dive

Eisai plans to appeal the EMA’s negative recommendation, hoping to break into a market analysts expect could eventually bring billions of dollars in sales for the Alzheimer’s drug.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Navigating Ad Regulations: Digital Compliance for Pharma Marketers

Pharma Marketing Network

In the ever-evolving digital landscape, pharma marketers must stay up to date with the latest ad regulations. Navigating the complex web of rules and regulations requires careful consideration and preparation. This includes understanding the various laws and regulations that govern digital advertising.

article thumbnail

Hemp Beverages: How this Growing Market Navigates US Regulations

XTalks

The market for hemp beverages has been growing rapidly in recent years. The passing of the 2018 Farm Bill, which legalized hemp production, boosted the market, allowing companies to explore hemp as a primary ingredient. Its branding and marketing strategies have resonated well with younger, health-conscious consumers.

article thumbnail

More federal regulators investigating Biogen's Alzheimer's drug

Bio Pharma Dive

In a regulatory filing, Biogen said the FTC and the SEC are looking for information about Aduhelm's approval and marketing, meaning the drug is now the focus of four government probes.

article thumbnail

Incyte withdraws cancer drug from FDA review after discussions with regulator

Bio Pharma Dive

The decision is a further sign of regulators' scrutiny of accelerated approvals for cancer therapies, an initiative that's led to several market withdrawals.

article thumbnail

Bluebird's next gene therapy gets backing from European regulator

Bio Pharma Dive

The treatment, for a progressive, often deadly brain disease, could soon become Bluebird's third approved product and one of only a handful of marketed gene therapies in the world.